Editorial
doi: 10.1136/bmj.321.7260.525.
The future of research into rotavirus vaccine
- PMID: 10968800
- PMCID: PMC1118429
- DOI: 10.1136/bmj.321.7260.525
Item in Clipboard
Editorial
The future of research into rotavirus vaccine
BMJ.
.
No abstract available
Comment in
-
Future of research into rotavirus vaccine. Cost effectiveness of vaccine is being assessed.BMJ. 2001 Jan 13;322(7278):106. BMJ. 2001. PMID: 11154636 Free PMC article. No abstract available.
-
Future of research into rotavirus vaccine. Developing countries must apply mathematics to take their own decisions.BMJ. 2001 Jan 13;322(7278):106-7. BMJ. 2001. PMID: 11154637 No abstract available.
Similar articles
-
Rotavirus vaccination and intussusception.Lancet. 1999 Sep 11;354(9182):956. doi: 10.1016/S0140-6736(05)75710-X. Lancet. 1999. PMID: 10489989 No abstract available.
-
Intussusception among recipients of rotavirus vaccine--US, 1998-1999.Ann Pharmacother. 1999 Sep;33(9):1020-1. Ann Pharmacother. 1999. PMID: 10492512 No abstract available.
-
Rotavirus W179-9 vaccine (Merck and Co).Drugs R D. 1999 Sep;2(3):220-1. doi: 10.2165/00126839-199902030-00018. Drugs R D. 1999. PMID: 10641234 No abstract available.
-
The new pentavalent rotavirus vaccine composed of bovine (strain WC3) -human rotavirus reassortants.Pediatr Infect Dis J. 2006 Jul;25(7):577-83. doi: 10.1097/01.inf.0000220283.58039.b6. Pediatr Infect Dis J. 2006. PMID: 16804425 Review.
-
Rotavirus vaccines in developed countries.Curr Opin Infect Dis. 2007 Jun;20(3):253-8. doi: 10.1097/QCO.0b013e32813aeaac. Curr Opin Infect Dis. 2007. PMID: 17471034 Review.
Cited by
-
Future of research into rotavirus vaccine. Cost effectiveness of vaccine is being assessed.BMJ. 2001 Jan 13;322(7278):106. BMJ. 2001. PMID: 11154636 Free PMC article. No abstract available.
-
Risk-benefit analysis: from a logical point of view.J Bioeth Inq. 2012 Jun;9(2):161-70. doi: 10.1007/s11673-012-9366-y. Epub 2012 Mar 21. J Bioeth Inq. 2012. PMID: 23180259
-
Mortality reduction benefits and intussusception risks of rotavirus vaccination in 135 low-income and middle-income countries: a modelling analysis of current and alternative schedules.Lancet Glob Health. 2019 Nov;7(11):e1541-e1552. doi: 10.1016/S2214-109X(19)30412-7. Lancet Glob Health. 2019. PMID: 31607466 Free PMC article.
-
Removing the age restrictions for rotavirus vaccination: a benefit-risk modeling analysis.PLoS Med. 2012;9(10):e1001330. doi: 10.1371/journal.pmed.1001330. Epub 2012 Oct 23. PLoS Med. 2012. PMID: 23109915 Free PMC article.
-
Human-animal chimeras for vaccine development: an endangered species or opportunity for the developing world?BMC Int Health Hum Rights. 2010 May 19;10:8. doi: 10.1186/1472-698X-10-8. BMC Int Health Hum Rights. 2010. PMID: 20482820 Free PMC article.
References
-
- Bernstein DI, Glass RI, Rodgers G, Davidson BL, Sack DA.for the US Rotavirus Vaccine Efficacy Group. Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children JAMA 19952731191–1196. - PubMed
-
- Rennels MB, Glass RI, Dennehy PH, Bernstein DI, Pichichero ME, Zito ET, et al. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines—report of the National Multicenter Trial. Pediatrics. 1996;97:7–13. - PubMed
-
- Joensuu J, Koskenniemi E, Pang XL, Vesikari T. Randomized placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet. 1997;350:1205–1209. - PubMed
-
- Santosham M, Moulton LH, Reid R, Croll J, Weatherholt R, Ward R, et al. Efficacy and safety of high-dose rhesus-human reassortant rotavirus vaccine in Native American populations. J Pediatr. 1997;131:632–638. - PubMed
-
- Intussusception among recipients of rotavirus vaccine—United States, 1998-1999. MMWR. 1999;48:577–581. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
